Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.58 |
| ▸ | ERBB2 | P04626 | 15/20 | 0.58 |
| ▸ | GAK | O14976 | 1/20 | 0.55 |
| ▸ | ERBB4 | Q15303 | 4/20 | 0.53 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.53 |
| ▸ | JAK3 | P52333 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4697985 | 0.95 | EGFR (0.57) | EGFRERBB2GAKERBB4ERBB3 | |
| SCHEMBL1094486 | 0.81 | EGFR (0.68) | EGFRERBB2GAKERBB4ERBB3 | |
| SCHEMBL5528646 | 0.79 | EGFR (0.66) | EGFRERBB2GAKERBB4ERBB3 | |
| SCHEMBL5524423 | 0.79 | EGFR (0.80) | EGFRERBB2GAKERBB4ERBB3 | |
| SCHEMBL4697984 | 0.78 | EGFR (0.57) | EGFRERBB2ERBB4ERBB3HDAC3 | |
| SCHEMBL4338866 | 0.77 | EGFR (0.70) | EGFRERBB2HDAC3HDAC4HDAC1 | |
| SCHEMBL14466953 | 0.76 | EGFR (0.68) | EGFRERBB2GAKERBB4ERBB3 | |
| SCHEMBL5002106 | 0.74 | EGFR (0.82) | EGFRERBB2GAKERBB4ERBB3 | |
| SCHEMBL5002100 | 0.74 | EGFR (0.82) | EGFRERBB2GAKERBB4ERBB3 | |
| SCHEMBL1105295 | 0.74 | EGFR (0.82) | EGFRERBB2GAKERBB4ERBB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234351-A1 | FUSED NITROGEN-COMPRISING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-1987037-A2 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007097470-A2 | FUSED NITROGEN- COMPRISING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234351-A1 | FUSED NITROGEN-COMPRISING HETEROCYCLIC COMPOUND | NR0B2, NR0B1, NR4A3 | EGFR 573/4885ERBB2 195/4885GAK 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.